AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) shows high virologic cure rates for naïve HCV
Enanta announced new data for AbbVie’s pan-genotypic chronic HCV treatment, MAVYRET™ (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis. Results showed with 8 weeks of MAVYRET, 100 percent of genotype 1, 2, 4, 5 and 6 patients achieved a SVR12 per protocol analysis. November 13, 2018